Pharma: Clinic Roundup
Thursday, March 29, 2012
Allergan Inc., of Irvine, Calif., said two Phase III trials of Botox (onabotulinumtoxinA) met their primary endpoints in overactive bladder, with data from both studies showing that Botox significantly reduced urinary incontinence episodes compared to placebo in patients not adequately managed by an anticholinergic treatment.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.